

## 英語論文

### 2024 年

1. Rubeiz CJ, Asero R, Betschel S, Craig T, Grumach A, Hide M, et al. Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria. *World Allergy Organization J.* 2024;17(1) 10.1016/j.waojou.2023.100858.
2. Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, et al. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. *J Allergy Clin Immunol.* 2024.
3. Oda Y, Fukunaga A, Takahagi S, Hide M. Palpebral angioedema in cholinergic urticaria. In: Gdse K, editor. *Hanbook of angioedema: Jaypee Brothers Medical Publishers Pvt Ltd;* 2024. p. 210.
4. Neisinger S, Sousa Pinto B, Ramanauskaite A, Bousquet J, Weller K, Metz M, et al. CRUSE® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. *Clin Transl Allergy.* 2024;14(1):e12328.
5. Morioka S, Aikyo T, Tanaka A, Matsubara D, Saito R, Iwamoto K, et al. Survey of hereditary angioedema episodes and quality of life impairment through a patient-participatory registry. *Journal of Cutaneous Immunology and Allergy.* 2024;7. DOI: 10.3389/jcia.2024.12626
6. Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. *Lancet.* 2024;403(10422):147-59.
7. Honda D, Hide M, Fukuda T, Koga K, Morita E, Moriwaki S, et al. Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial. *World Allergy Organization Journal.* 2024;17(3):100882.
8. Petersen RS, Fijen LM, Apfelbacher C, Magerl M, Weller K, Aberer W, et al. A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema. *J Allergy Clin Immunol Pract.* 2024;12(6):1614-21.
9. Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, et al. Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. *J Allergy Clin Immunol Glob.* 2024;3(4):100317.
10. Fukunaga A, Kakei Y, Murakami S, Kan Y, Masuda K, Jinnin M, et al. Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study. *Frontiers in Immunology.* 2024;15. DOI: 10.3389/fimmu.2024.1441478
11. Numata T, Iwamoto K, Matsunae K, Miyake R, Suehiro M, Yanagida N, et al. A

- Staphylococcus epidermidis strain inhibits the uptake of Staphylococcus aureus derived from atopic dermatitis skin into the keratinocytes. *J Dermatol Sci.* 2024;113(3):113-20.
12. Hide M, Kishimoto M, Kotera I, Oh A, Inoue Y, Yamamoto BA, et al. Analysis of disease burden in patients with hereditary angioedema from Japan by patient-reported outcomes. *J Dermatol.* 2024. DOI: 10.1111/1346-8138.17421
  13. Buttgereit T, Aulenbacher F, Gutsche A, Kolkhir P, Weller K, Vera Ayala C, et al. The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation. *Clin Exp Allergy.* 2024. DOI: 10.1111/cea.14527
  14. Hide M. Marcus Maurer, MD (1966–2024). *J Dermatol* (in press) DOI: 10.1111/1346-8138.17456
  15. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Mohammad Porras N, Matsuo Y, et al. Omalizumab is effective and safe in chronic inducible urticaria (CIndU): real-world data from a large multi-national UCARE study. *Allergy* (in press)
  16. Morioke S, Tanaka A, Moriwaki M, Hide M. A case of chronic spontaneous urticaria with wheals lasting for more than a week. *J Dermatol* (in press) DOI: 10.1111/1346-8138.17480
  17. Ashizawa S, Kan T, Takahagi S, Kawai M, Toda S, Iwasaki Y, Karakawa S, Hide M, Tanaka A. Retrospective evaluation of oral propranolol delivery strategy in 25 cases of infantile hemangioma. *J Plastic Reconstructive Surgery* (in press) DOI: 10.53045/jprs.2023-0016

## 2023 年

1. Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C, et al. A concept for integrated care pathways for atopic dermatitis-A GA(2) LEN ADCARE initiative. *Clin Transl Allergy.* 2023;13(9):e12299.
2. Yanase Y, Matsubara D, Takahagi S, Tanaka A, Ozawa K, Hide M. Basophil Characteristics as a Marker of the Pathogenesis of Chronic Spontaneous Urticaria in Relation to the Coagulation and Complement Systems. *International Journal of Molecular Sciences.* 2023;24(12), 10320.
3. Yamamoto B, Honda D, Ohsawa I, Iwamoto K, Horiuchi T, Fukunaga A, et al. Burden of illness seen in hereditary angioedema in Japanese patients: Results from a patient reported outcome survey. *Intractable Rare Dis Res.* 2023;12(1):35-44.
4. Takimoto-Ito R, Kambe N, Kogame T, Nomura T, Izawa K, Jo T, et al. Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan. *Allergol Int.* 2023;72(2):297-305.
5. Takahagi S, Hide M, Aoyama Y, Fukunaga A, Murota H. A single-blind, randomized,

- crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain). *Medicine (Baltimore)*. 2023;102(23):e33971.
6. Seirin-Lee S, Matsubara D, Yanase Y, Kunieda T, Takahagi S, Hide M. Mathematical-based morphological classification of skin eruptions corresponding to the pathophysiological state of chronic spontaneous urticaria. *Communications Medicine*. 2023;3(1):171.
  7. Saeki H, Akiyama M, Abe M, Igarashi A, Imafuku S, Ohya Y, et al. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis. *J Dermatol*. 2023;50(1):e1-e19.
  8. Saeki H, Akiyama M, Abe M, Igarashi A, Imafuku S, Ohya Y, et al. English version of Japanese guidance for biologics in treating atopic dermatitis. *J Dermatol*. 2023;50(10):e311-e22.
  9. Nakahara T, Izuhara K, Onozuka D, Saeki H, Nunomura S, Takenaka M, et al. Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study). *Clin Exp Allergy*. 2023;53(2):233-8.
  17. Naito Y, Matsumura S, Hada Y, Tanaka M, Takahagi S, Hide M. Pustular eruption on the palms and soles associated with zinc allergy and perspiration. *JAAD Case Rep*. 2023;36:92-5.
  18. Matsubara D, Kunieda T, Yanase Y, Takahagi S, Uchida K, Kawaguchi T, et al. Time Course of Priming Effect of TF Inducers on Synergistic TF Expression and Intra-Cellular Gap Formation of Human Vascular Endothelial Cells via the Extrinsic Coagulation Cascade. *Int J Mol Sci*. 2023;24(15), 12388.
  19. Li PH, Pawankar R, Thong BY, Fok JS, Chantaphakul H, Hide M, et al. Epidemiology, Management, and Treatment Access of Hereditary Angioedema in the Asia Pacific Region: Outcomes From an International Survey. *J Allergy Clin Immunol Pract*. 2023;11(4):1253-60.
  20. Kogetsu A, Isono M, Aikyo T, Furuta J, Goto D, Hamakawa N, et al. Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan. *Research Involvement and Engagement*. 2023;9(1):107.
  21. Kaplan A, Lebwohl M, Gimenez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. *Allergy*. 2023;78(2):389-401.
  22. Kanamoto M, Takahagi S, Aoyama S, Kido Y, Nakanishi M, Naito M, et al. The expression of prolyl isomerase Pin1 is expanded in the skin of patients with atopic dermatitis and facilitates IL-33 expression in HaCaT cells. *J Dermatol*. 2023;50(4):462-71.
  23. Hide M, Wang Y, Dote N, Miyakawa K, Sugiura K, Ishida K. Safety, efficacy, and

- pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study. *J Dermatol.* 2023; ;50(11):1473-7.
24. Hide M, Ohsawa I, Nurse C, Yu M. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study. *J Dermatol.* 2023;50(11):1381-91.
  25. Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T, et al. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study. *Allergol Int.* 2023;72(2):286-96.
  26. Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, et al. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study. *Allergol Int.* 2023.
  27. Chinuki Y, Kohno K, Hide M, Hanaoka K, Okabe T, Fukunaga A, et al. Efficacy and safety of omalizumab in adult patients with wheat-dependent exercise-induced anaphylaxis: Reduction of in vitro basophil activation and allergic reaction to wheat. *Allergol Int.* 2023;72(3):444-50.

## **2022 年**

1. Zuberbier T, Dorr T, Aberer W, Alvaro M, Angier E, Arasi S, et al. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA(2)LEN position paper. *Allergy.* 2022;77(6):1736-50.
2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy.* 2022;77(3):734-66.
3. Yoshikawa Y, Imamura M, Yamauchi M, Hayes CN, Aikata H, Okamoto W, et al. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. *BMC Cancer.* 2022;22(1):1232.
4. Yanagida N, Takahagi S, Tanaka A, Hide M. Propylthiouracil-induced Alopecia Accompanying Hypohidrosis and Onychomadesis. *Acta Derm Venereol.* 2022;102:adv00763.
5. Yanagida N, Takahagi S, Aoyama Y, Tanaka A, Hide M. Anhidrosis accompanied by cholinergic urticaria-like rash and dermal pain in a patient with Sjogren's syndrome. *J Dermatol.* 2022;49(6):666-70.
6. Urabe T, Miyoshi H, Narasaki S, Yanase Y, Uchida K, Noguchi S, et al. Characterization

- of intracellular calcium mobilization induced by remimazolam, a newly approved intravenous anesthetic. *PLoS One*. 2022;17(2):e0263395.
7. Takahagi S, Okamoto M, Ishii K, Tanaka A, Mizuno H, Harada N, et al. Clinical and histological characterization of transient dermal pain triggered by sweating stimuli. *Allergol Int*. 2022;71(3):362-72.
  8. Takahagi S, Kamegashira A, Inomata N, Fukunaga A, Nakahara T, Hayama K, et al. Impact of physicians' clinical experience and workplace on patients' care of urticaria in Japan: A sub-analysis of a nation-wide cross-sectional web questionnaire survey. *Journal of Cutaneous Immunology and Allergy*. 2022;5(3):106-8.
  9. Suehiro M, Numata T, Murakami E, Takahashi M, Saito R, Morioko S, et al. Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis. *Dermatol Ther*. 2022;35(7):e15526.
  10. Saito R, Takahagi S, Nakano F, Furutani K, Mihara S, Numata T, et al. A survey on subtypes and clinical characteristics of 1061 patients with urticaria in the primary care institutes in Japan. *J Dermatol*. 2022;49(12):1255-62.
  11. Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. *Allergol Int*. 2022;71(4):448-58.
  12. Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, et al. English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. *J Dermatol*. 2022;49(10):e315-e75.
  13. Numata T, Takahagi S, Ishii K, Morioko S, Kan T, Mizuno H, et al. Immunological Changes of Basophil Hyperreactivity to Sweat in Patients With Well-Controlled Atopic Dermatitis. *Front Immunol*. 2022;13:883605.
  14. Nakamura R, Tanaka A, Kinoshita H, Ishii K, Hide M. Minocycline-induced anaphylaxis mediated by antigen-specific immunoglobulin E. *J Dermatol*. 2022;49(2):e61-e2.
  15. Miyake R, Iwamoto K, Sakai N, Matsunae K, Aziz F, Sugai M, et al. Uptake of *Staphylococcus aureus* by keratinocytes is reduced by interferon-fibronectin pathway and filaggrin expression. *J Dermatol*. 2022;49(11):1148-57.
  16. Metz M, Bernstein JA, Gimenez-Arnau AM, Hide M, Maurer M, Sitz K, et al. Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria. *World Allergy Organ J*. 2022;15(11):100716.
  17. Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. *World Allergy Organ J*. 2022;15(3):100627.
  18. Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, et al. The

- international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. *Allergy*. 2022;77(7):1961-90.
19. Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. *World Allergy Organ J*. 2022;15(3):100627
  20. Maurer M, Gimenez-Arnau A, Bernstein JA, Chu CY, Danilycheva I, Hide M, et al. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study. *Allergy*. 2022;77(7):2175-84.
  21. Matsubara D, Yanase Y, Ishii K, Takahagi S, Tanaka A, Ozawa K, et al. Basophils activation of patients with chronic spontaneous urticaria in response to C5a despite failure to respond to IgE-mediated stimuli. *Front Immunol*. 2022;13:994823.
  22. Koga Y, Yokooji T, Ogino R, Taogoshi T, Takahagi S, Ishii K, et al. A novel detection method for cross-linking of IgE-receptors by autoantibodies in chronic spontaneous urticaria. *Allergol Int*. 2022;71(1):94-102.
  23. Kan T, Tanaka A, Kanamoto M, Morioke S, Takahagi S, Hide M. Longitudinal prevalence of atopic dermatitis among freshmen at Hiroshima University between 2002 and 2019. *J Dermatol*. 2022;49(7):724-8.
  24. Kan T, Takahagi S, Matsubara D, Murakami E, Kawai M, Hide M, et al. Clinical course of more than 10 years in a patient with extensive skin burns who received cultured epidermal autograft transplantation. *Regen Ther*. 2022;19:154-7.
  25. Hide M, Kaplan AP. Concise update on the pathogenesis of chronic spontaneous urticaria (CSU). *J Allergy Clin Immunol*. 2022;150(6):1403-4.
  26. Amano A, Takahagi S, Kinoshita H, Nakamura R, Ishii K, Hide M. Anaphylaxis due to thiamine disulfide phosphate, a derivative of vitamin B1; a case report and literature review. *Allergol Int*. 2022;71(3):414-6.
  27. Taogoshi T, Shibata Y, Uno H, Yokooji T, Tanaka M, Hide M, et al. Classification of Skin Injury Risk Caused by Extravasation of Electrolyte Solutions or Infusions in a Rat Model. *Biol Pharm Bull*. 2022;45(9):1254-8.

## 2021 年

1. Yanase Y, Takahagi S, Ozawa K, Hide M. The Role of Coagulation and Complement Factors for Mast Cell Activation in the Pathogenesis of Chronic Spontaneous Urticaria. *Cells*. 2021;10(7):1759.
2. Yanase Y, Matsuo Y, Takahagi S, Kawaguchi T, Uchida K, Ishii K, et al. Coagulation factors induce human skin mast cell and basophil degranulation via activation of complement 5

- and the C5a receptor. *J Allergy Clin Immunol.* 2021;147(3):1101-4 e7.
3. Tanaka A, Morioka S, Ohya Y, Shimojo N, Takahashi M, Tanaka M, et al. Comparison of the time course of atopic dermatitis from birth to 19 years old among generations of patients in Japan. *J Dermatol.* 2021;48(10):1602-6.
  4. Tanaka A, Morioka S, Ohya Y, Shimojo N, Shinichi A, Shizukawa H, et al. Time course of disease severity from birth to 19 years old in patients with moderate to severe atopic dermatitis in adulthood. *The Journal of Dermatology.* 2021;48(5):e205-e6.
  5. Tanaka A, Ishii K, Takahagi S, Hide M. Temporary wheat allergy in the postpartum period. *Allergol Int.* 2021;70(1):159-60.
  6. Takahara Y, Kan T, Teshima Y, Matsubara D, Takahagi S, Tanaka A, et al. Malignant melanoma with in-transit metastases refractory to programmed cell death-1 inhibitor successfully treated with local interferon- $\beta$  injections: A case report. *Mol Clin Oncol.* 2021;15(4):212.
  7. Takahagi S, Tanaka M, Morioka S, Suehiro M, Tanaka A, Hide M. Long-term remission of severe livedoid vasculopathy treated with a short course of intravenous immunoglobulin. *Journal of Cutaneous Immunology and Allergy.* 2021;4(6):189-90.
  8. Takahagi S, Numata T, Tanaka A, Hide M. Iatrogenic cutaneous lymphoid hyperplasia induced by squaric acid dibutyl ester. *Contact Dermatitis.* 2021;85(1):88-90.
  9. Takahagi S, Kamegashira A, Inomata N, Fukunaga A, Nakahara T, Hayama K, et al. Impact of physicians' clinical experience and workplace on patients' care of urticaria in Japan: A sub - analysis of a nation - wide cross - sectional web questionnaire survey. *Journal of Cutaneous Immunology and Allergy.* 2021;5(3):106-8.
  10. Saito R, Tanaka A, Takahagi S, Tanaka M, Hide M. Pemphigus foliaceus with inconsistent findings between clinical features and titres of antidesmoglein autoantibodies. *Australas J Dermatol.* 2021;62(1):e148-e9.
  11. Ryo S, Hajime S, Shunsuke T, Akio T, Michihiro H. A Case of Pruritus with Symptomatic Dermographism Previously Treated as Eczema. *Atopic Dermatitis and Pruritus: Interesting Cases.* 2021. DOI: doi.org/10.5005/jp/books/18337\_26
  12. Otsuka R, Tanaka A, Takahashi M, Saito R, Iwamoto K, Takahagi S, et al. The relationship between the development of erythroderma in patients with atopic dermatitis and the avoidance of anti-inflammatory topical drugs. *Allergol Int.* 2021;70(3):376-8.
  13. Ohsawa I, Honda D, Suzuki Y, Fukuda T, Kohga K, Morita E, et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial. *Allergy.* 2021;76(6):1789-99.
  14. Ohsawa I, Fukunaga A, Imamura S, Iwamoto K, Tanaka A, Hide M, et al. Survey of actual conditions of erythema marginatum as a prodromal symptom in Japanese patients with

- hereditary angioedema. *World Allergy Organ J.* 2021;14(2):100511.
15. Morioka S, Takahagi S, Kawano R, Fukunaga A, Harada S, Ohsawa I, et al. A validation study of the Japanese version of the Angioedema Activity Score (AAS) and the Angioedema Quality of Life Questionnaire (AE-QoL). *Allergology International.* 2021;70(4):471-9.
  16. Maurer M, Aygoren-Pursun E, Banerji A, Bernstein JA, Balle Boysen H, Busse PJ, et al. Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. *J Allergy Clin Immunol.* 2021;148(6):1526-32.
  17. Matsubara D, Takahagi S, Saito R, Kamegashira A, Tanaka A, Hide M. Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. *J Dermatol.* 2021;48(1):56-63.
  18. Kunitsu T, Ueba S, Nakajima R, Nonomura K, Maruo Y, Hide M. Fasting-associated urticaria and/or anaphylaxis: A case report. *Allergol Int.* 2021;70(2):271-3.
  19. Iwamoto K, Yamamoto B, Ohsawa I, Honda D, Horiuchi T, Tanaka A, et al. The diagnosis and treatment of hereditary angioedema patients in Japan: A patient reported outcome survey. *Allergol Int.* 2021;70(2):235-43.
  20. Iio S, Oka S, Tanaka S, Sumioka A, Tsuboi A, Nojima T, et al. Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis. *Sci Rep.* 2021;11(1):20163.
  21. Hide M, Horiuchi T, Ohsawa I, Andresen I, Fukunaga A. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks. *Allergol Int.* 2021;70(1):45-54.
  22. Hide M. Malcolm Watson Greaves. *The Journal of Dermatology.* 2021;48(3):251-.
  23. Hamakawa N, Kogetsu A, Isono M, Yamasaki C, Manabe S, Takeda T, et al. The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project. *Res Involv Engagem.* 2021;7(1):9.
  24. Gonçalo M, Giménez-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. *Br J Dermatol.* 2021;184(2):226-36.
  25. Giménez-Arnau AM, DeMontojoye L, Asero R, Cugno M, Kulthanan K, Yanase Y, et al. The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells. *J Allergy Clin Immunol Pract.* 2021;9(6):2195-208.

## 国際学会発表

### 2024年

1. Hide M, Fukunaga a, Yagami A. TAS5315, Bruton's tyrosine kinase inhibitor, in patients



with chronic spontaneous urticaria with an inadequate response to H1-antihistamines: phase 2a, randomized, double-blind study. EAACI Congress 2024, Valencia, Italy, May 31, 2024

2. Hide M. The background of mast cell activation in chronic spontaneous urticaria. 2024 Chinese Allergy School, & 9th International forum on Allergic Disease Management. Tianjin, China, May 26, 2024 (Invited)

### **2023 年**

1. Hide M. Acute urticaria: are there differences in pathogenesis and treatment? How often does it develop into chronic urticaria? Epidemiological analysis and effect of proactive treatment with antihistamine. UCARE2023, Sanpaolo, Brazil, Dec 8, 2023 (Invited)
2. Hide M. Diagnostic challenges in HAE. APAAACI2023, Singapore, Oct 24, 2023 (Invited)
3. Hide M, Audhya PK, Smith MD, M. Yea CM. Investigating on-demand use of oral sebetralstat in adults and adolescents with hereditary angioedema: Multicenter, double-blind, randomized, placebo-controlled, phase 3 KONFIDENT trial and open-label extension. The 72th annual meeting of the Japanese Society of Allergology, English session, Tokyo, Japan, Oct 8, 2022
4. Hide M. Understanding mediators, mechanisms and inflammation pathways in chronic spontaneous urticaria helps us to treat our patients. The 25<sup>th</sup> World Congress of Dermatology 2023, Singapore, Apr 7, 2023 (invited)

### **2022 年**

1. Hide M, Hayama K, Ramsey A, Maurer M, Lheritier K, Zharkov A, Haemmerle S, Nikolaev I. Remibrutinib improves CSU in patients with low or high IgE. 6th GA<sup>2</sup>LEN Global Urticaria Forum (GUF) Congress, Berlin, Germany, Dec 8, 2022
2. Hide M, Kishimoto M, Kotera I, Oh A, Inoue Y, Yamamoto BA, Noto S. Burden of disease and health state perceptions in patients with hereditary angioedema in Japan: quantification of patient-reported outcomes. APAAACI 2022, Manila, Philippines, Dec 5, 2022
3. Hide M. The international WAO/EAAACI Guidelines for the management of Hereditary Angioedema the 2021 revision and update. APAAACI 2022, Dec 5, 2022 (Invited)
4. Hide M, Ohsawa I, Nurse C, Yu M. Efficacy and Safety of Lanadelumab in Japanese patients with hereditary Angioedema: Results from a phase 3, open-label study. The 71th annual meeting of the Japanese Society of Allergology, English session, Tokyo, Japan, Oct 8, 2022
5. Hide M. Insights into urticaria for diagnosis and management. 2022 International Congress of 50th anniversary KAAACI, Soule, Korea/Web, May 7, 2022 (Invited)

## 2021 年

1. Hide M. Pathogenesis and treatment of chronic spontaneous urticaria and cholinergic urticaria. 17th Congress of the Baltic Association of Dermatovenereologists. Kaunas, Lithuania/Web, Sep 17, 2021 (Invited)
2. Hide M. Progress of the treatment of atopic dermatitis and sweat allergy. 17th Congress of the Baltic Association of Dermatovenereologists. Kaunas, Lithuania/Web, Sep 17, 2021 (Invited)
3. Hide M. Cholinergic Urticaria and UCARE meeting in Hiroshima. 66th Spanish Group of Contact Dermatitis and Cutaneous Allergy, Murcia, Spain, Sep 24, 2021 (Invited)
4. Hide M. Update of Hereditary Angioedema. APAAACI 2021 International Conference. Singapore, Oct 16, 2021 (Invited)
5. Hide M. Itch of urticaria. 46th Ann Meeting of JSID/Morning, Tokyo, Japan/Web, Dec 5, 2021
6. Hide M. Opening remarks. UCARE2021. Hiroshima, Japan/Web, Dec 9, 2021 (Congress chair)
7. Hide M. Prevalence and burden of chronic inducible urticaria in Japan. UCARE2021. Hiroshima, Japan/Web, Dec 10, 2021 (Invited)
8. Hide M. Complete response with ligelizumab in CSU: A composite score analysis. UCARE2021. Hiroshima, Japan/Web, Dec 10, 2021
10. Hide M. Ligelizumab further improves disease-activity in CSU patients previously on omalizumab. UCARE2021. Hiroshima, Japan/Web, Dec 10, 2021